Atractylenolide III

Atractylenolide III, also known as ICodonolactone, constitutes the primary active compound of the Atractylodes rhizome and exhibits the capability to induce apoptosis in lung cancer cells. It is recognized for its oral efficacy as a gastroprotective agent .

Atractylenolide III, at concentrations ranging from 1 to 100 μM over 48 hours, induces apoptosis in A549 cells, as evidenced by the activation of caspase-3 and caspase-9 and the cleavage of PARP¹.

Atractylenolide III, in concentrations between 1 and 100 μM over a period of 72 hours, inhibits proliferation and angiogenesis, as indicated by tube formation, in Human Umbilical Vein Endothelial Cells (HUVECs)¹.

Atractylenolide III, at concentrations of 1-100 μM, inhibits the production of proinflammatory cytokines (IL-6, IL-1β, TNF-α, and IL-8) induced by thymic stromal lymphopoietin (TSLP) in HMC-1 cells⁴.

Atractylenolide III, administered orally at doses of 5 and 10 mg/kg, demonstrates gastroprotective effects and reduces gastric ulcers induced by 70% ethanol in rats by up to 70%².

Atractylenolide III, when administered at 30 mg/kg through oral gavage for either 14 or 28 days, alleviates depressive- and anxiogenic-like behaviors in rat models of depression. This effect is observed in models induced by lipopolysaccharide (LPS) and chronic unpredictable mild stress (CUMS)⁵.

Atractylenolide III, administered orally at doses of 5 and 10 mg/kg, demonstrates gastroprotective effects and reduces gastric ulcers induced by 70% ethanol in rats by up to 70%².

Atractylenolide III, when administered at 30 mg/kg through oral gavage for either 14 or 28 days, alleviates depressive- and anxiogenic-like behaviors in rat models of depression. This effect is observed in models induced by lipopolysaccharide (LPS) and chronic unpredictable mild stress (CUMS)⁵.

溶解方案(细胞实验)

DMSO 中的溶解度 : 50 mg/mL (201.35 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

溶解方案(动物实验)

"方案 一": "请依序添加每种溶剂：10% DMSO 40% PEG300 5% Tween-80 45% SalineSolubility: ≥ 2.5 mg/mL (10.07 mM); 澄清溶液 此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水 定容至 1 mL。生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。"

"方案 二": "请依序添加每种溶剂：10% DMSO 90% (20% SBE-β-CD in Saline)Solubility: ≥ 2.5 mg/mL (10.07 mM); 澄清溶液 此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中，混合均匀。2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。"

"方案 三": "请依序添加每种溶剂：10% DMSO 90% Corn OilSolubility: ≥ 2.5 mg/mL (10.07 mM); 澄清溶液 此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。"